Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Nav1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

¹Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Japan
²Drug Metabolism&Pharacokinetics Research Labo, Daiichi Sankyo Co. Ltd., Japan
³Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Japan
⁴Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi-Sankyo Co., Ltd., Japan
⁵R&D Planning & Management Department, Daiichi Sankyo Co., Ltd., Japan
⁶Research function, Daiichi Sankyo Co., Ltd., Japan
⁷Daiichi Sankyo Co., Ltd., Japan
⁸School of Pharmaceutical Sciences, University of Shizuoka, Japan

↵* Corresponding Author:
Daigo Asano, Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, N/A, 140-8710, Japan. E-mail: asano.daigo.vi{at}daiichisankyo.co.jp